CTT Pharmaceutical Holdings, Inc. (CTTH)
USD 0.07
(88.78%)
USD 0.07
(88.78%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 49.2 Thousand | 25 Thousand |
| Cost of Revenue | 6398.00 | 6398.00 | - | - | - | - |
| Gross Profit | -6398.00 | -6398.00 | - | - | 49.2 Thousand | 25 Thousand |
| Operating Expenses | 35.69 Thousand | 102.4 Thousand | 148.45 Thousand | 584.31 Thousand | 639.84 Thousand | 1.73 Million |
| Selling, General and Administrative Expenses | 35.69 Thousand | 102.4 Thousand | 148.45 Thousand | 584.31 Thousand | 639.84 Thousand | 1.73 Million |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 42.09 Thousand | 108.8 Thousand | 148.45 Thousand | 584.31 Thousand | 639.84 Thousand | 1.73 Million |
| Operating Income | -42.09 Thousand | -108.8 Thousand | -148.45 Thousand | -584.31 Thousand | -590.64 Thousand | -1.7 Million |
| Interest Expense | - | - | - | - | 208.00 | 18.35 Thousand |
| Income Tax Expense | -167.89 Thousand | -228.48 Thousand | -236.55 Thousand | -206.29 Thousand | -171.86 Thousand | -161.14 Thousand |
| Earnings before Tax | -42.21 Thousand | -53.44 Thousand | -133.07 Thousand | -586.34 Thousand | -585.86 Thousand | -1.72 Million |
| Net Income | -42.21 Thousand | -53.44 Thousand | -133.07 Thousand | -586.34 Thousand | -585.86 Thousand | -1.72 Million |
| Earnings Per Share Basic | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.04 |
| Earnings Per Share Diluted | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.04 |
| Weighted Average Shares Outstanding | 50.52 Million | 49.42 Million | 50.07 Million | 47.57 Million | 47.57 Million | 47.07 Million |
| Weighted Average Shares Outstanding (Diluted) | 50.52 Million | 49.42 Million | 50.07 Million | 47.57 Million | 47.57 Million | 47.07 Million |
| Gross Margin | - | - | - | - | 1.00 | 1.00 |
| EBIT Margin | - | - | - | - | -12.00 | -68.32 |
| Profit Margin | - | - | - | - | -11.91 | -69.12 |
| EBITDA | -35.69 Thousand | -44.71 Thousand | -133.07 Thousand | -586.34 Thousand | -585.65 Thousand | -1.7 Million |
| Earnings Before Tax Margin | - | - | - | - | -12.00 | -68.32 |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | 6398.00 | 6398.00 | - | - | - |
| Gross Profit | - | -6398.00 | -6398.00 | - | - | - |
| Operating Expenses | 61.98 Thousand | 35.69 Thousand | 13.42 Thousand | 871.00 | 9826.00 | 25.09 Thousand |
| Selling, General and Administrative Expenses | 61.98 Thousand | - | 13.42 Thousand | 871.00 | 9826.00 | 25.09 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 61.98 Thousand | 42.09 Thousand | 19.82 Thousand | 871.00 | 9826.00 | 25.09 Thousand |
| Operating Income | -61.98 Thousand | -42.09 Thousand | -19.82 Thousand | -870.00 | -9830.00 | -25.09 Thousand |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -43.27 Thousand | -167.89 Thousand | -43.81 Thousand | 39.58 Thousand | -122.08 Thousand | -41.58 Thousand |
| Earnings before Tax | -61.98 Thousand | -42.21 Thousand | -6427.00 | -872.00 | -9826.00 | -25.09 Thousand |
| Net Income | -61.98 Thousand | -42.21 Thousand | -6427.00 | -872.00 | -9826.00 | -25.09 Thousand |
| Earnings Per Share Basic | -0.00 | - | -0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | - | -0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 50.19 Million | 50.52 Million | 48.39 Million | 48.39 Million | 48.39 Million | 48.34 Million |
| Weighted Average Shares Outstanding (Diluted) | 50.19 Million | 50.52 Million | 48.39 Million | 48.39 Million | 48.39 Million | 48.34 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -61.98 Thousand | - | -13.42 Thousand | -870.00 | -9830.00 | -25.09 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
NP5
EAX
MEE
DGIK
BNZIW
KABRAEXTRU